<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097045</url>
  </required_header>
  <id_info>
    <org_study_id>Biomed 510-CLP-07</org_study_id>
    <nct_id>NCT00097045</nct_id>
  </id_info>
  <brief_title>Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C</brief_title>
  <official_title>Phase 2 Study of Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <brief_summary>
    <textblock>
      This study is designed to compare the safety, tolerability and antiviral effects of omega&#xD;
      interferon administered alone to omega interferon administered with ribavirin in the&#xD;
      treatment of subjects with chronic Hepatitis C virus (HCV) infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Omega interferon is administered subcutaneously daily for up to 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV RNA levels at clinically relevant timepoints</measure>
  </primary_outcome>
  <enrollment>90</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega interferon</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 18 years to 64 years&#xD;
&#xD;
          -  Signed and dated written informed consent form&#xD;
&#xD;
          -  Infection with HCV genotype 1&#xD;
&#xD;
          -  Two HCV RNA levels greater than or equal to 100,000 International Units per mL (IU/mL)&#xD;
             at least seven days apart within 6 weeks prior to randomization&#xD;
&#xD;
          -  One alanine aminotransferase level greater than the upper limit of normal between&#xD;
             three months and twelve months prior to randomization&#xD;
&#xD;
          -  At least one alanine aminotransferase level greater than the upper limit of normal&#xD;
             between three months and twelve months prior to randomization&#xD;
&#xD;
          -  For the duration of treatment with study drug for all subjects and for the duration of&#xD;
             treatment with study drug plus an additional six months for subjects who take&#xD;
             ribavirin, attenuation of the potential of the subject to become pregnant, or to&#xD;
             impregnate a sexual partner, by either:&#xD;
&#xD;
               1. the use of an approved contraceptive method (e.g., IUD, oral contraceptive, or&#xD;
                  double-barrier method), or&#xD;
&#xD;
               2. definitive exclusion by surgery, radiation, menopause or vasectomy&#xD;
&#xD;
          -  For women of childbearing potential, negative serum Beta HCG pregnancy test within 14&#xD;
             days prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any additional plausible cause for chronic liver disease, including active infection&#xD;
             by other viruses known or suspected to cause hepatitis&#xD;
&#xD;
          -  Ascites or other current evidence of portal hypertension&#xD;
&#xD;
          -  Child-Pugh classification B or C liver disease&#xD;
&#xD;
          -  Clinically apparent jaundice or a total bilirubin exceeding 2 mg/dL (Subjects with&#xD;
             Gilbert's Syndrome who meet all other inclusion and exclusion criteria may be admitted&#xD;
             to the study with a total bilirubin greater than 2 mg/dL)&#xD;
&#xD;
          -  Hemoglobin &lt;12 g/dL&#xD;
&#xD;
          -  A platelet count of less than 100,000 per mm3&#xD;
&#xD;
          -  A total white blood cell count of less than 3,000 per mm3&#xD;
&#xD;
          -  An absolute neutrophil count of less than 1,500 per mm3&#xD;
&#xD;
          -  Abnormal thyroid function (Subjects requiring thyroid replacement and who have stable,&#xD;
             normal thyroid function may be admitted to the study)&#xD;
&#xD;
          -  History of significant renal dysfunction&#xD;
&#xD;
          -  History of significant or unstable cardiac disease&#xD;
&#xD;
          -  Concurrent alcohol abuse or illicit drug use&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Prior usage of an interferon&#xD;
&#xD;
          -  Concurrent usage of any antiviral therapy, including another interferon, during the&#xD;
             study&#xD;
&#xD;
          -  Any concurrent infectious disease requiring antimicrobial treatment&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus&#xD;
&#xD;
          -  Positive test for illicit drugs&#xD;
&#xD;
          -  A history of malignancy (except for previously cured squamous cell or basal cell&#xD;
             carcinoma)&#xD;
&#xD;
          -  Known hypersensitivity to interferons or ribavirin or related compounds&#xD;
&#xD;
          -  A concurrent diagnosis of depression that has not been stable for at least 60 days&#xD;
             prior to randomization&#xD;
&#xD;
          -  Usage of an investigational drug within the 30 days prior to randomization; or the&#xD;
             planned usage of an investigational drug other than omega interferon during the course&#xD;
             of the current study&#xD;
&#xD;
          -  Prior randomization to this study&#xD;
&#xD;
          -  Any condition which, at the discretion of the investigator, would render an individual&#xD;
             an inappropriate candidate for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>November 17, 2004</study_first_submitted>
  <study_first_submitted_qc>November 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2004</study_first_posted>
  <last_update_submitted>August 21, 2007</last_update_submitted>
  <last_update_submitted_qc>August 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2007</last_update_posted>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Omega Interferon</keyword>
  <keyword>Interferon</keyword>
  <keyword>HCV genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon omega 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

